In a report released yesterday, Steven Mah from TD Cowen maintained a Buy rating on BioLife Solutions (BLFS – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $11.19.
According to TipRanks, Mah is an analyst with an average return of -19.0% and a 20.75% success rate. Mah covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Ginkgo Bioworks Holdings, and Thorne HealthTech.
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $23.25.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $26.89 and a one-year low of $10.48. Currently, BioLife Solutions has an average volume of 460.2K.
Based on the recent corporate insider activity of 164 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLFS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
